BioSpace News Archive

Kairos Pharma, Ltd., a privately held clinical stage biotechnology company focused on drug resistance and immunotherapy for cancer, announced that its activated T cell therapy, KROS 201, has received FDA approval to proceed with a Phase 1 clinical trial in patients with recurrent glioblastoma, a type of brain cancer.

Eton Pharmaceuticals, Inc. (Nasdaq: ETON) and XGen Pharmaceuticals DJB, Inc. today announced the commercial availability of Rezipres® (ephedrine hydrochloride) injection.

XORTX Therapeutics Inc. announces that it submitted a clinical trial application with Health Canada for a XRX-OXY-101 bridging pharmacokinetics study.

Assure Holdings Corp., a provider of intraoperative neuromonitoring and remote neurology services, reported financial results for the fourth quarter and full year ended December 31, 2021.

Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today the U.S. Food and Drug Administration (FDA) has approved Corium’s ADLARITY (donepezil transdermal system) as a treatment for patients with mild, moderate, or severe dementia of the Alzheimer’s type.

Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced the appointment of David Dornan, Ph.D. as the Company’s Chief Scientific Officer.

Akumin Inc. will host a conference call at 8:00 a.m. Eastern Time , March 17, 2022, to discuss its year-end 2021 financial results.

Nektar Therapeutics (NASDAQ:NKTR) will hold an analyst and investor conference call with Nektar management today, Monday, March 14, 2022, at 5:00 a.m. Pacific Standard Time (PST), following this morning’s update from Bristol-Myers Squibb and Nektar on the pivotal Phase 3 PIVOT IO-001 study.

Fresenius Kabi Receives U.S. Food and Drug Administration 510(k) Clearance for Wireless Agilia ® Connect Infusion System with Vigilant ® Software Suite-Vigilant ® Master Med Technology.

Biogen Inc. (Nasdaq: BIIB) today announced new data and updates from its SPINRAZA® (nusinersen) and spinal muscular atrophy (SMA) research program aimed at improving clinical outcomes for people impacted by the disease, including the ASCEND, RESPOND and NURTURE studies.